Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.276
+0.016 (6.19%)
Dec 26, 2024, 11:22 AM EST
Northwest Biotherapeutics Company Description
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally.
The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.
The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors.
The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Linda Powers |
Contact Details
Address: 4800 Montgomery Lane Bethesda, Delaware 20814 United States | |
| Phone | 240 497 9024 |
| Website | nwbio.com |
Stock Details
| Ticker Symbol | NWBO |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US66737P6007 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Linda F. Powers J.D. | Chairperson, Chief Executive Officer, President, Chief Financial Officer and Chief Accounting Officer |
| Dr. Alton L. Boynton Ph.D. | Founder, Chief Scientific Officer, Secretary and Director |
| Dr. Marnix L. Bosch M.B.A., Ph.D. | Chief Technical Officer |
| Leslie J. Goldman | Senior Vice President and General Counsel |
| David Innes | Vice President of Investor Relations |